ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > 100.82% increase

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Jul 08, 2022 10:22am

82 Views

Post# 34810816

RE:RE:RE:100.82% increase

G1945V wrote:

Gbathat wrote: My TDAmeritrade account is showing a NASDAQ PMN pps of $13.20 USD.

Is that a glitch??? !!!

There is not any other data, charts, etc.

But looks promising I'd say! Hopefully it sticks and we're live on NASDAQ

Not yet !

G1945V